Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pyxis Oncology, Inc.

0.9150
-0.0649-6.62%
Post-market: 0.91510.0001+0.01%17:29 EDT
Volume:499.70K
Turnover:464.99K
Market Cap:56.36M
PE:-0.69
High:0.9878
Open:0.9799
Low:0.9100
Close:0.9799
Loading ...

Company Profile

Company Name:
Pyxis Oncology, Inc.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
44
Office Location:
321 Harrison Avenue,11th Floor, Suite 1,Boston,Massachusetts,United States
Zip Code:
02118
Fax:
- -
Introduction:
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
John Flavin
Director,Chairman of the Board
Lara Sullivan
Chief Executive Officer and Director
Darren Cline
Director
Freda Lewis Hall
Director
Mark Chin
Director
Thomas Civik
Director

Shareholders

Name
Position
Lara Sullivan
Chief Executive Officer and Director
Ritu Shah
Chief Operating Officer
Pamela Connealy
Chief Financial Officer
Jay Feingold
Chief Medical Officer
Ronald Herbst
Chief Scientific Officer